时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
研究问题
The purpose of reporting this case is to provide insights for the management of similar patients in follow-up care.
方法
Highlights •Exogenous insulin antibody syndrome (EIAS) primarily manifests in diabetic patients receiving exogenous insulin therapy.；Timely adjustment of the treatment regimen is crucial to mitigate the advancement of diabetes complications in patients with EIAS.；Glucagon-like peptide-1 receptor agonist may represent an effective therapeutic strategy for overweight or obese EIAS patients.
核心结论
Individuals harboring HLA-B8, DR3, and C4AQS alleles exhibit reduced levels of insulin antibodies, whereas those with the DR7 allele demonstrate markedly elevated insulin antibody levels.22 Due to current limitations in laboratory testing methodologies, only qualitative assessments of IA can be performed, precluding the quantification of IA titers.Research on the genetic susceptibility of EIAS, particularly concerning HLA, is relatively limited.
局限
Basically, insulin concentration aligns with levels post-seroconversion within the initial 3 months following treatment modification.18 However, in this instance, the patient's insulin concentration only approximated post-seroconversion levels in the final 6 months post-treatment adjustment, signifying a delayed seroconversion compared to the majority of patients.HLA-II genes consist of DR and DQ regions, with DQ molecules composed of A and B polymorphic chains.；Individuals harboring HLA-B8, DR3, and C4AQS alleles exhibit reduced levels of insulin antibodies, whereas those with the DR7 allele demonstrate markedly elevated insulin antibody levels.22 Due to current limitations in laboratory testing methodologies, only qualitative assessments of IA can be performed, precluding the quantification of IA titers.Research on the genetic susceptibility of EIAS, particularly concerning HLA, is relatively limited.；However, we observed that the HLA typing of this EIAS patient, specifically DRB10301/DQA10501/DQB102016, is consistent with that of one individual previously diagnosed with IAS.
对本项目的价值
中等价值：属「代谢 / 内分泌 / 肝肾老化」方向；代谢 / 内分泌 / 肝肾老化的界面栏目可用作本项目文献库与综述素材。 ｜ 价值分 2.6/5（★★★☆☆）
全文来源
PubMed PMC JATS（正文 14,571 字符，题名指纹 0.83，已过 PubMed PMCID 官方关联 + 题名指纹 + 正文长度归属校验）
原文题录
- 中文题名：外源性胰岛素抗体综合征患者 GLP-1 受体激动剂治疗六年随访：病例报告
- 英文标题：Six-Year Follow-Up of Glucagon-like peptide-1 receptor agonist (GLP1-RA) Therapy in a Patient With Exogenous Insulin Antibody Syndrome: A Case Report.
- 期刊与标识：AACE endocrinology and diabetes · PMID 42979053 · DOI 10.1016/j.aed.2025.12.008 · PMC PMC13728291